**5.3.88 YAM80**

There is no drug information available for YAM80 searching literature and chemical databases. YAM80 is evaluated in a phase II study (NCT00886977) for safety and efficacy in ALS patients.

### **5.3.89 Zidovudine**

The antiviral drug zidovudine did not show a benefit in ALS patients (Westarp et al., 1993).

### **5.3.90 Preclinical agents**

The following agents have shown promising results in preclinical assessment, but no clinical trials have been conducted:

Azathioprine, glycine, the tripeptide zVAD-fmk, AM-1241, celastrol, dantrolene, nordihydroguaiaretic acid, RO-28-2653, L-arginine, 5-hydroxytryptophan, N-acetylated alphalinked acidic dipeptidase, mechano-growth factor (MGF), hepatocyte growth factor (HGF), glial-derived neurotrophic factor (GDNF), promethazine and other anti-histaminergic drugs, calcium disodium EDTA, toluloxy propane, ammonium tetramolybdate (for details, see (Mitsumoto, 2009; Zoccolella et al., 2007)), and cannabis (Carter et al., 2010).
